...
首页> 外文期刊>The Lancet >Mycosis fungoides and Sezary syndrome.
【24h】

Mycosis fungoides and Sezary syndrome.

机译:蕈样真菌病和Sezary综合征。

获取原文
获取原文并翻译 | 示例

摘要

Mycosis fungoides and Sezary syndrome are the most common of the cutaneous T-cell lymphomas, which are a heterogeneous group of neoplasms that affect the skin as a primary site. Although the aetiologies of mycosis fungoides and Sezary syndrome are unknown, important insights have been gained in the immunological and genetic perturbations that are associated with these diseases. Unlike some B-cell lymphomas, cutaneous T-cell lymphomas as a group are rarely if ever curable and hence need chronic-disease management. New approaches to treatments are being investigated and include biological and cytotoxic drugs, phototherapy, and monoclonal antibodies that are directed towards novel molecular targets. New molecular technologies such as complementary-DNA microarray have the potential to increase the accuracy of diagnosis and provide important prognostic information. Treatments can be combined to greatly improve clinical outcome without substantially increasing toxic effects in advanced disease that is otherwise difficult to treat. Although present treatment strategies are generally not curative, there is hope that experimental treatments, particularly immunotherapy, might eventually reverse or suppress the abnormalities of mycosis fungoides and Sezary syndrome to the point at which they become non-life-threatening, chronic diseases.
机译:蕈样真菌病和Sezary综合征是皮肤T细胞淋巴瘤中最常见的一种,是一组异质性肿瘤,它们会影响皮肤作为主要部位。尽管尚无关于蕈样真菌病和Sezary综合征的病因,但在与这些疾病相关的免疫和遗传扰动方面已获得重要见解。与某些B细胞淋巴瘤不同,皮肤T细胞淋巴瘤几乎无法治愈,因此需要进行慢性病治疗。正在研究新的治疗方法,其中包括针对新型分子靶标的生物和细胞毒性药物,光疗和单克隆抗体。诸如互补DNA微阵列之类的新分子技术具有提高诊断准确性并提供重要预后信息的潜力。可以联合使用多种疗法,以大大改善临床结果,而又不会实质性地提高否则难以治疗的晚期疾病的毒性作用。尽管目前的治疗策略通常不能治愈,但仍希望实验性治疗(尤其是免疫治疗)最终可以逆转或抑制蕈样肉芽肿和Sezary综合征的异常,从而使其成为不危及生命的慢性疾病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号